Ra Pharmaceuticals, Inc. (RARX) related to its sale to UCB S.A. Under the terms of the agreement, each share of RARX common stock will be converted into the right to receive $48.00 in cash per share of RARX common stock owned. The transaction value is expected to be approximately $2.1 billion.